Kaken Pharmaceutical Co., Ltd. (KKPCF)

Market Cap	1.06B
Revenue (ttm)	593.75M
Net Income (ttm)	130.55M
Shares Out	n/a
EPS (ttm)	3.45
PE Ratio	8.12
Forward PE	n/a
Dividend	1.30 (4.87%)
Ex-Dividend Date	Mar 28, 2025

Volume	1,577
Average Volume	60
Open	28.00
Previous Close	26.78
Day's Range	26.78 - 28.00
52-Week Range	22.30 - 28.96
Beta	0.14
RSI	97.49
Earnings Date	May 12, 2025

About Kaken Pharmaceutical

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surger...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1917
• Employees: 1,135
• Stock Exchange: OTCMKTS
• Ticker Symbol: KKPCF

Financial Performance

In 2023, Kaken Pharmaceutical's revenue was 72.04 billion, a decrease of -1.29% compared to the previous year's 72.98 billion. Earnings were 8.03 billion, an increase of 47.52%.

Financial numbers in JPY